

## Research paper

## Prevalence of depressive symptoms in people aged 50 years and older: A retrospective cross-sectional study

Julia Christl<sup>a,\*</sup>, Pascal Grumbach<sup>a,d</sup>, Christiane Jockwitz<sup>b,c</sup>, Natalia Wege<sup>a</sup>,  
Svenja Caspers<sup>b,c,1</sup>, Eva Meisenzahl<sup>a,1</sup>

<sup>a</sup> Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany

<sup>b</sup> Institut für Anatomie I, Medizinische Fakultät & Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

<sup>c</sup> Institut für Neurowissenschaften und Medizin (INM-1), Forschungszentrum Jülich, Jülich, Germany

<sup>d</sup> Institut für Neurowissenschaften und Medizin, Brain & Behavior (INM-7), Forschungszentrum Jülich, Jülich, Germany

## ARTICLE INFO

## Keywords:

Prevalence  
Depressive symptoms  
Cross-sectional study  
Cognitive function  
Aging  
Lifestyle  
Polyneuropathy

## ABSTRACT

**Background:** Depression is a serious health problem worldwide and is often associated with disability and reduced quality of life. In aging societies, early recognition of depression in older adults is highly relevant. Therefore, this study investigated the prevalence of depressive symptoms in individuals aged 50 and older with the aim to identify those at risk for major depression.

**Methods:** We performed a retrospective cross-sectional study with data from 1000BRAINS to assess depressive symptoms in a sample of 1017 healthy adults aged 50 and older. The prevalence and dimension of depressive symptoms were measured by the Beck Depression Inventory II, and differences between demographic, clinical, and lifestyle-associated variables and the prevalence of depressive symptoms were analyzed.

**Results:** Depressive symptoms were present in 21.3 % of the participants and were minimal in 14.2 %, mild in 4.5 %, moderate in 1.8 %, and severe in 0.8 %. The prevalence of depressive symptoms was highest in the age group 50 to 59 years, and the prevalence of severe depressive symptoms decreased with increasing age. A positive family history of depression, cognitive impairment, medication intake, and polyneuropathy were associated with significantly higher levels of depressive symptoms.

**Limitations:** The retrospective cross-sectional design and evaluation of depressive symptoms by a self-rating instrument may limit the generalizability of the results.

**Conclusion:** This study supports earlier findings of a higher prevalence of depressive symptoms among older adults. The group aged 50 to 59 appears to be particularly affected. Additionally, poor physical health, greater cognitive impairment, and sex-specific factors appear to contribute to depressive symptomatology.

## 1. Introduction

Depression is often associated with disability and reduced quality of life (James et al., 2018). With prognostic calculations placing depression at the forefront of disease burden by 2030 (Mathers and Loncar, 2006), the imperative for innovative research into early recognition and prediction has never been more critical. This need is particularly pronounced among older adults. For example, research in the US by Kessler et al. (2005) and Steffens et al. (2009) showed the significant prevalence of major depressive episodes among those over 60; this trend is mirrored

globally, whereby levels vary across demographics and are associated with factors such as sex, physical health, and cognitive impairment (Djernes, 2006; Luppá et al., 2012; Aziz and Steffens, 2013; Busch et al., 2013; Streit et al., 2023; Volkert et al., 2013). Furthermore, global populations are aging rapidly, particularly in high-income countries; e. g., from 2022 to 2050, the proportion of the population aged 65 years and older is extrapolated to increase from 10 % in 2022 to 16 % in 2050 (Aziz and Steffens, 2013; United Nations, 2022).

In their study, Kessler et al. (2005) reported a 10.8 % lifetime prevalence of major depressive episodes in those aged 60 and older, and

\* Corresponding author at: Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Bergische Landstr. 2, 40629 Düsseldorf, Germany.

E-mail address: [Julia.christl@lvr.de](mailto:Julia.christl@lvr.de) (J. Christl).

<sup>1</sup> These authors contributed equally.

<https://doi.org/10.1016/j.jad.2024.12.099>

Received 7 August 2024; Received in revised form 20 December 2024; Accepted 27 December 2024

Available online 30 December 2024

0165-0327/© 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

the Aging, Demographics, and Memory Study found a prevalence of clinical depression of 11.1 % in participants aged 71 and older, with higher rates in those with dementia and pain (Steffens et al., 2009). Djernes (2006) reviewed international studies and found prevalences of major depressive disorder (MDD) of 0.9 % to 9.4 % in older adults ( $\geq 65$  years) living in private households and 14 % to 42 % in older adults in institutional settings. Rates were higher in women and those with physical illnesses, cognitive impairments, loneliness, and a history of depression. Luppa et al. (2012) reported prevalences of 4.6 % to 9.3 % for MDD and 4.5 % to 37.4 % for depressive disorders in those aged 75 and older.

In older people, depression interacts significantly with physical health issues such as vascular risk factors, cerebrovascular incidents, cerebral infarctions, white matter hyperintensities, myocardial infarction, and coronary artery disease (Aziz and Steffens, 2013; Taylor et al., 2013). It also shows a bidirectional relationship with obesity, stroke, and coronary heart disease (Penninx et al., 2013; Gold et al., 2020). The strong link with cardiovascular and cerebrovascular conditions suggests shared mechanisms (Alexopoulos, 2005, 2019). Additionally, depression is common in neurodegenerative disorders such as Alzheimer's and Parkinson's disease as well as Lewy body and frontotemporal dementia, highlighting its complex relationship with cognitive and neurological health (Burgut et al., 2006). Patients with polypharmacy and those receiving drugs such as beta-blockers and proton pump inhibitors (PPI) also have a higher risk for depression (Qato et al., 2018; Laudisio et al., 2018).

Epidemiological studies on the prevalence of depressive symptoms across age groups are important because they help to develop early recognition strategies and intervention options to better address late-life depression (Blazer, 2003). The German Health Interview and Examination Survey for Adults (DEGS) found that the lifetime prevalence of depression increases with age: The prevalence was highest in the 60 to 69 age group (17.3 %), and lowest in the 18 to 29 age group (6.3 %) (Scheidt-Nave et al., 2012; Kamtsiuris et al., 2013). Depressive symptoms were most prevalent in the 20 to 29 age group (9.9 %) (Busch et al., 2013), which was in line with the US Behavioral Risk Factor Surveillance System findings (Strine et al., 2008). Busch et al. (2013) also found that lower socioeconomic status was linked to higher depression risk. The German National Cohort (NAKO) found the highest lifetime depression rates in the 50 to 59 age group and similar prevalences of depressive symptoms in the 20 to 29 and 50 to 59 age groups (10.0 % vs 9.3 %, respectively) (Streit et al., 2023); furthermore, lower educational level, positive family history, anxiety, and stress were associated with depressive symptoms (Streit et al., 2023). A meta-analysis of 25 studies found a higher prevalence of dimensional than categorical depression (Volkert et al., 2013), and an earlier study found that about 27 % of adults aged 60 and older reported depressive symptoms but only 0.8 % met criteria for MDD (Blazer et al., 1987).

In summary, evaluating the prevalence of depressive symptoms in late middle and older age is crucial given the ongoing demographic shifts and because early detection is a prerequisite for preventing severe disease progression and chronicity. Subclinical depressive symptoms that do not fulfil the criteria of a MDD may be part of a clinical high risk state (CHR—D) of depression and associated with functional decline, increased mortality (Meisenzahl et al., 2024; Biella et al., 2019; Benasi et al., 2021). Preventive strategies are important because in primary care settings, depressive symptoms that are not clinical depression are the most important risk factor for depression in older age (Schoevers et al., 2006). Therefore, this study aimed to examine the prevalence of depressive symptoms stratified by severity in individuals aged 50 years and older. In addition, differences regarding severity of depression symptoms and sociodemographic variables, cognition, comorbidities as well as medication were assessed.

## 2. Methods

Participants were recruited from the 1000BRAINS population (Caspers et al., 2014), a subgroup of the Heinz Nixdorf Recall (HNR) study 10-year follow-up cohort (Schmermund et al., 2002) and the HNR MultiGeneration Study (Kowall et al., 2021). The HNR studies collected health data and relevant social and environmental information from people in the Ruhr metropolitan area. Between 2000 and 2003, 4814 people were enrolled in the HNR study. Participants were interviewed annually about their health and closely examined again after 5 and 10 years. The HNR MultiGeneration Study included 1237 spouses and 1660 adult children of HNR study participants and started recruitment in 2013.

In 1000BRAINS, the baseline assessment comprised standardized, semi-structured interviews and questionnaires, collection of biomaterial, and magnetic resonance imaging (MRI; Caspers et al., 2014). Subjects not eligible for MRI measurement were excluded. Sociodemographic characteristics included age, sex, marital status, and education level (according to the International Standard Classification of Education 97 (ISCED 97) criteria) (UNESCO United Nations Educational and Scientific and Cultural Organization, 2003). Depressive symptoms were evaluated by the self-report Beck Depression Inventory II (BDI-II; Hautzinger et al., 2006), which comprises 21 items about cognitive-affective (e.g., sadness, pessimism, fear of failure, loss of happiness, and feelings of guilt) and somatic symptoms (e.g., loss of appetite, sleeping problems, and tiredness) during the preceding two weeks and categorized depending on the sum score in no depression (BDI II  $< 9$ ), minimal (BDI II = 9–13), mild (BDI II = 14–19), moderate (BDI II = 20–28) and high (BDI II  $> 28$ ) depression (Storch et al., 2004; Bridwell et al., 2015). The questionnaires asked about quality of life (Nuremberg Life Quality Questionnaire; Oswald and Fleischmann, 1997), daily activity (Nuremberg Daily Activities Questionnaire; Oswald and Fleischmann, 1997), behavioral and personality changes (Jülicher Inventar zu frontalem Verhalten, adapted from the frontal behavioral inventory (FBI), Kertesz et al., 1997 and Freiburg Personality Inventory (FPI); Fahrenberg et al., 2010), lifestyle factors (i.e., physical activity in hours per week (h/wk), cigarettes smoked per day, and alcohol and lifetime illegal drug use), and life satisfaction (Caspers et al., 2014). Information was also collected on physical complaints and somatic diseases; body mass index; hearing loss; visual impairment; and neurological and/or psychiatric treatment, including family history. Medications were obtained from the HNR study (Schmermund et al., 2002) and assigned to the following categories: antihypertensives, anticoagulants, antidiabetics, lipid reducers, PPIs, inhalers for lung diseases such as chronic obstructive pulmonary disease, vitamin D, levothyroxine, analgesic agents, antidepressants, hypnotics, anticonvulsants, and Parkinson drugs. Finally, the DemTect dementia screening test (to evaluate verbal memory, working memory, word fluency, and cognitive flexibility; Kalbe et al., 2004) were performed. 1000BRAINS was approved by the University of Essen ethics committee, and all participants gave written informed consent.

For the current retrospective cross-sectional analysis, we categorized 1000BRAINS participants into age-stratified subgroups (50–59, 60–69, 70 and older) and evaluated severity of depressive symptoms self-assessed with the BDI-II as well as depressive symptomatology separated in cognitive (7 items), affective (5 items) and somatic domains (9 items) in the subgroups (Almeida et al., 2023). Moreover, differences between somatic factors such as physical illnesses, medication intake, and cognitive function regarding depressive symptom severity was examined.

### 2.1. Statistical analysis

We analyzed frequencies or means and standard deviations (SDs) of depressive symptom severity in the various age groups. Differences in depressive symptoms stratified by age, sex and education were

evaluated by Chi-square tests for categorical variables, and *t*-test for continuous variables. Differences of demographic, clinical, and lifestyle variables regarding depressive symptoms were analyzed by univariate analysis of variance (ANOVA). Corrections were made for age, sex, and education level. Results of the BDI-II were separated in cognitive, affective and somatic domains according to Almeida et al. (2023). Differences in cognitive, affective and somatic domains across the various age groups were analyzed by ANOVA and corrected for sex, educational level and physical complaints using the related item of the FPI. Analyses were performed with SPSS 28.0 (IBM Corp.). A *p*-value of <0.05 was considered statistically significant.

### 3. Results

#### 3.1. Descriptive statistics 1000BRAINS cohort

The analysis included 1017 participants (456 [44.8 %] women and 561 [55.2 %] men). Only 37 participants were aged 80 years and older (maximum age, 87 years), so all patients aged 70 (*N* = 350) and older were combined into one subgroup.

#### 3.2. Prevalence of depressive symptoms

Table 1 provides descriptive statistics of demographic, lifestyle, medical, and quality-of-life variables stratified by depressive symptom severity within the 1000BRAINS cohort, categorized based on Beck Depression Inventory II (BDI-II) cut-off scores. The cohort is divided into three groups: no depressive symptoms (*N* = 770), minimal depressive symptoms (*N* = 139), and manifest depressive symptoms (*N* = 70). Regarding depressive symptoms at the cut-off of >13, mild depressive symptoms were the most prevalent, followed by moderate and severe ones. When minimal depressive symptoms were included, the proportion of participants with depressive symptoms increased from 7.1 to 21.3 %. Demographic variables show that the percentage of females increases with depressive symptom severity, from 42.1 % in the no symptoms group to 58.6 % in the manifest group. Similarly, participants with lower educational attainment and those living alone are more prevalent in groups with higher depressive symptoms.

#### 3.3. Depressive symptoms stratified by age, sex and education

Table 2 shows descriptive statistics of clinical variables and depression-associated measures stratified by age groups. The mean BDI-II score was similar in the whole sample and the age groups. Depressive symptoms were most prevalent in the age group 50 to 59 years. Severe depressive symptoms were also most prevalent in this group, and their prevalence decreased with increasing age; in contrast, minimal depressive symptoms increased with increasing age. Participants 70 years and older did not present any moderate or severe depressive symptoms (Table 2, Fig. 1). As expected, with increasing age, the number of participants with suspected mild cognitive impairment and suspected dementia increased (Table 2). The sex distribution was not significantly different between the age groups ( $X^2(1) = 3.973$ ;  $p = 0.137$ ). The oldest age group reported significantly less about a history or positive family history of psychiatric treatment. Physical complaints were similar across the age groups, although age-related hearing loss and cataracts increased with increasing age. All musculoskeletal diseases, except artificial joint disease, peaked at around 60 to 69 years. With increasing age, the number of medications increased ( $F(1,973) = 5.37$ ;  $p = 0.021$ ), particularly antihypertensives, anticoagulants, lipid reducers, and anti-diabetics (Table S1).

Table 3 shows descriptive statistics of clinical variables and depression-associated measures stratified by sex. Women had a significantly higher BDI-II score than men and more frequently reported a personal as well as a positive family history of psychiatric treatment. Men had significantly lower DemTect-scores than women.

**Table 1**

Descriptive statistics of demographic, lifestyle and medical variables across depressive symptom severity in the 1000BRAINS cohort.

| Variables                                    | Total                      | Depressive symptom severity |                             |                              |
|----------------------------------------------|----------------------------|-----------------------------|-----------------------------|------------------------------|
|                                              |                            | No depressive symptoms      | Minimal depressive symptoms | Manifest depressive symptoms |
| BDI-II cut-off                               |                            | 0–8                         | 9–13                        | ≥14                          |
|                                              | <i>N</i> = 1017<br>(100.0) | <i>N</i> = 770<br>(78.7)    | <i>N</i> = 139<br>(14.2)    | <i>N</i> = 70 (7.1)          |
| <b>Demographic variables</b>                 |                            |                             |                             |                              |
| Female                                       | 456<br>(44.8)              | 324 (42.1)                  | 77 (55.4)                   | 41 (58.6)                    |
| Age, years                                   | 66.48<br>(±7.55)           | 66.41<br>(±7.47)            | 67.40<br>(±8.11)            | 64.08<br>(±7.11)             |
| Native language                              | 976<br>(96.0)              | 743 (96.5)                  | 132 (95.0)                  | 65 (92.9)                    |
| German                                       |                            |                             |                             |                              |
| ISCED97 education level                      |                            |                             |                             |                              |
| - Low                                        | 61 (6.0)                   | 43 (5.6)                    | 10 (7.2)                    | 6 (8.6)                      |
| - Intermediate                               | 558<br>(54.9)              | 398 (51.8)                  | 87 (62.6)                   | 47 (67.1)                    |
| - High                                       | 397<br>(39.1)              | 328 (42.7)                  | 42 (30.2)                   | 17 (24.3)                    |
| Living with a partner                        | 789<br>(78.4)              | 610 (80.1)                  | 109 (79.0)                  | 41 (59.4)                    |
| Living alone                                 |                            |                             |                             |                              |
| - Single                                     | 41 (4.0)                   | 28 (3.6)                    | 7 (5.0)                     | 5 (7.1)                      |
| - Divorced                                   | 74 (7.3)                   | 51 (6.6)                    | 9 (6.5)                     | 13 (18.6)                    |
| - Widowed                                    | 102<br>(10.0)              | 73 (9.5)                    | 13 (9.4)                    | 10 (14.3)                    |
| <b>Psychiatric variables</b>                 |                            |                             |                             |                              |
| BDI-II                                       | 5.43<br>(±5.63)            | 3.20<br>(±2.54)             | 10.32<br>(±1.34)            | 20.29<br>(±6.84)             |
| Past or current psychiatric treatment        | 166<br>(17.2)              | 96 (13.1)                   | 34 (26.0)                   | 32 (47.1)                    |
| Positive family history for psych. disorders | 182<br>(18.2)              | 128 (16.8)                  | 27 (19.7)                   | 22 (33.3)                    |
| - First-grade relative                       | 107<br>(10.5)              | 76 (9.9)                    | 17 (12.2)                   | 13 (18.6)                    |
| - Second-grade relative                      | 47 (4.6)                   | 32 (4.2)                    | 6 (4.3)                     | 6 (8.6)                      |
| - Third-grade relative                       | 23 (2.3)                   | 16 (2.1)                    | 3 (2.2)                     | 3 (4.3)                      |
| DemTect                                      | 14.70<br>(±2.49)           | 14.90<br>(±2.44)            | 14.23<br>(±2.54)            | 13.96<br>(±2.34)             |
| - No cognitive impairment                    | 812<br>(81.5)              | 635 (83.9)                  | 103 (76.9)                  | 49 (71.0)                    |
| - Mild cognitive impairment                  | 174<br>(17.5)              | 116 (15.3)                  | 30 (22.4)                   | 19 (27.5)                    |
| - Suspected dementia                         | 10 (1.0)                   | 6 (0.8)                     | 1 (0.7)                     | 1 (1.4)                      |
| <b>Lifestyle variables</b>                   |                            |                             |                             |                              |
| Regular physical activity                    | 806<br>(80.0)              | 619 (81.6)                  | 111 (82.2)                  | 52 (74.3)                    |
| Physical activity, h/week                    | 4.68<br>(±5.57)            | 4.65<br>(±5.29)             | 4.88<br>(±6.32)             | 4.17<br>(±6.17)              |
| Smoking                                      | 110<br>(11.0)              | 84 (11.1)                   | 15 (10.9)                   | 9 (13.0)                     |
| - Cigarettes per day                         | 13.42<br>(±8.85)           | 12.76<br>(±8.42)            | 15.73<br>(±8.15)            | 14.56<br>(±13.79)            |
| Alcohol consumed per week                    | 8.58<br>(±11.49)           | 8.93<br>(±11.22)            | 7.53<br>(±12.18)            | 6.76<br>(±12.00)             |
| Illegal drug use                             | 30 (2.9)                   | 13 (1.7)                    | 8 (5.8)                     | 9 (13.0)                     |
| <b>Quality of life</b>                       |                            |                             |                             |                              |
| NLQ                                          | 132.7<br>(±17.3)           | 137.4<br>(±12.5)            | 120.8<br>(±15.9)            | 100.8<br>(±22.5)             |
| NAA                                          | 53.0<br>(±10.6)            | 53.8 (±9.8)                 | 51.9<br>(±11.7)             | 47.1<br>(±15.5)              |
| ABC-D                                        | 18.6<br>(±4.4)             | 18.0 (±3.3)                 | 20.2 (±5.6)                 | 22.0 (±7.2)                  |
| FBI                                          | 8.8<br>(±6.1)              | 7.7 (±5.2)                  | 10.6 (±5.3)                 | 17.5 (±8.5)                  |

(continued on next page)

Table 1 (continued)

| Variables                              | Total            | Depressive symptom severity |                             |                              |
|----------------------------------------|------------------|-----------------------------|-----------------------------|------------------------------|
|                                        |                  | No depressive symptoms      | Minimal depressive symptoms | Manifest depressive symptoms |
| BDI-II cut-off                         |                  | 0–8                         | 9–13                        | ≥14                          |
|                                        | N = 1017 (100.0) | N = 770 (78.7)              | N = 139 (14.2)              | N = 70 (7.1)                 |
| Somatic variables                      |                  |                             |                             |                              |
| Physical complaints, FPI               | 2.48 (±2.26)     | 1.95 (±1.82)                | 3.86 (±2.32)                | 5.6 (±2.81)                  |
| Age-related hearing loss               | 155 (15.5)       | 116 (15.3)                  | 27 (19.7)                   | 8 (11.9)                     |
| Other hearing loss                     | 132 (13.3)       | 101 (13.3)                  | 18 (13.3)                   | 11 (16.2)                    |
| Hearing aid                            | 78 (7.8)         | 59 (7.8)                    | 11 (8.1)                    | 6 (8.8)                      |
| Cataract                               | 201 (20.6)       | 147 (19.8)                  | 30 (22.9)                   | 15 (21.7)                    |
| - Operation performed                  | 120 (59.7)       | 90 (61.2)                   | 19 (63.3)                   | 4 (26.7)                     |
| Glaucoma                               | 49 (5.1)         | 34 (4.7)                    | 11 (8.6)                    | 1 (1.5)                      |
| - Operation performed                  | 4 (8.2)          | 2 (5.9)                     | 0 (0.0)                     | 1 (100.0)                    |
| Musculoskeletal diseases               |                  |                             |                             |                              |
| - Joint diseases                       | 334 (33.4)       | 237 (31.3)                  | 57 (41.6)                   | 28 (40.6)                    |
| - Artificial joint                     | 25 (2.5)         | 14 (1.8)                    | 8 (5.8)                     | 2 (2.9)                      |
| - Disc prolapse                        | 207 (20.7)       | 150 (19.8)                  | 34 (24.8)                   | 16 (23.2)                    |
| - Polyneuropathy                       | 140 (14.0)       | 85 (11.2)                   | 31 (22.6)                   | 17 (25.0)                    |
| Past or current neurological treatment | 215 (21.5)       | 143 (18.8)                  | 42 (30.7)                   | 24 (35.8)                    |
| BMI                                    | 27.35 (±4.17)    | 27.3 (±4.1)                 | 27.4 (±4.3)                 | 27.6 (±4.8)                  |
| - Underweight                          | 1 (0.1)          | 1 (0.1)                     | –                           | –                            |
| - Normal weight                        | 291 (29.4)       | 218 (29.1)                  | 42 (30.7)                   | 21 (30.4)                    |
| - Preobesity                           | 453 (45.7)       | 356 (47.5)                  | 57 (41.6)                   | 25 (36.2)                    |
| - Obesity                              | 246 (24.8)       | 175 (23.3)                  | 38 (27.7)                   | 23 (33.3)                    |
| Medication intake                      |                  |                             |                             |                              |
| Quantity of medication taken           | 1.88 (±1.97)     | 1.81 (±1.96)                | 2.12 (±2.05)                | 2.29 (±2.03)                 |
| Antihypertensives                      | 494 (48.6)       | 370 (48.1)                  | 68 (48.9)                   | 38 (54.3)                    |
| Lipid reducers                         | 183 (18.0)       | 142 (18.4)                  | 21 (15.1)                   | 16 (22.9)                    |
| Proton pump inhibitors                 | 115 (11.3)       | 77 (10.0)                   | 20 (14.4)                   | 17 (24.3)                    |
| Anticoagulants                         | 177 (17.4)       | 131 (17.0)                  | 27 (19.4)                   | 12 (17.1)                    |
| Antidiabetics                          | 82 (8.1)         | 63 (8.2)                    | 13 (9.4)                    | 2 (2.9)                      |
| Levothyroxine                          | 171 (16.8)       | 122 (15.8)                  | 30 (21.6)                   | 15 (21.4)                    |
| Analgesic agents                       | 59 (5.8)         | 40 (5.2)                    | 10 (7.2)                    | 8 (11.4)                     |
| Inhalers for lung diseases             | 40 (3.9)         | 32 (4.2)                    | 6 (4.3)                     | 1 (1.4)                      |
| Parkinson drugs                        | 17 (1.7)         | 10 (1.3)                    | 3 (2.2)                     | 3 (4.3)                      |
| Anticonvulsants                        | 17 (1.7)         | 7 (0.9)                     | 6 (4.3)                     | 3 (4.3)                      |
| Vitamin D                              | 29 (2.9)         | 14 (1.8)                    | 11 (7.9)                    | 4 (5.7)                      |
| Hypnotics                              | 2 (0.2)          | 0 (0.0)                     | 1 (0.7)                     | 1 (1.4)                      |
| Antidepressants                        | 95 (9.4)         | 47 (6.1)                    | 22 (15.8)                   | 22 (31.4)                    |

Numbers present either absolute numbers plus percent or mean plus standard deviation; frequencies are given for the participants with valid data records for the respective measure; missing Beck Depression Inventory II (BDI-II) values n = 38; ABC-D, Activities-Specific Balanced Confidence Scale; alcohol consumption per week in drinking units (glass of wine, beer, spirits); BMI, body mass index in weight in kg/height in m<sup>2</sup> (underweight <18.49, normal weight 18.5–24.9, preobesity 25–29.9, obesity ≥ 30); FPI = Freiburger personality inventory; ISCED97, International Standard Classification of Education 97; FBI, Frontal Behavioral Inventory; NLQ, Nuremberg Life Quality Questionnaire; NAA, Nuremberg Daily Activities Questionnaire; TBI = traumatic brain injury.

Table 2

Descriptive statistics of clinical variables across the age groups.

| Variables                                    | Age groups                     |                                |                                | p-Value                          |
|----------------------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------|
|                                              | 50–59 y<br>N = 233 (22.9)      | 60–69 y<br>N = 434 (42.7)      | 70–87 y<br>N = 350 (34.4)      |                                  |
| Clinical variables                           |                                |                                |                                |                                  |
| BDI-II                                       | 5.64 (±6.70)<br>[4.77–6.52]    | 5.45 (±6.00)<br>[4.88–6.03]    | 5.26 (±4.17)<br>[4.81–5.71]    | 0.726 <sup>1</sup>               |
| Depression                                   | 23 (10.1)<br>[6.2–14.1]        | 31 (7.3)<br>[4.8–9.8]          | 16 (4.8)<br>[2.5–7.2]          | 0.058 <sup>2</sup>               |
| - No depression                              | 175 (77.1)<br>[66.0–88.2]      | 335 (79.4)<br>[72.1–86.6]      | 260 (78.8)<br>[73.0–84.6]      | 0.792 <sup>2</sup>               |
| - Minimal depression                         | 29 (12.8)<br>[1.7–23.9]        | 56 (13.3)<br>[6.0–20.5]        | 54 (16.4)<br>[10.5–22.2]       | 0.378 <sup>2</sup>               |
| - Mild depression                            | 13 (5.7)<br>[0–16.8]           | 15 (3.6)<br>[0–10.8]           | 16 (4.8)<br>[0–10.7]           | 0.413 <sup>2</sup>               |
| - Severe depression                          | 6 (2.6)<br>[0–13.7]            | 12 (2.8)<br>[0–10.1]           | 0 (0.0) –<br>[0–10.1]          | 0.009 <sup>2</sup><br>(b, c)     |
| Positive family history for psych. disorders | 59 (25.8)<br>[20.1–31.4]       | 82 (19.2)<br>[15.4–23.0]       | 41 (12.0)<br>[8.5–15.4]        | <0.001 <sup>2</sup><br>(b, c)    |
| - First-grade relative                       | 32 (13.7)<br>[3.7–23.7]        | 51 (11.8)<br>[5.1–17.0]        | 24 (6.9)<br>[1.0–12.7]         | 0.016 <sup>2</sup><br>(b, c)     |
| - Second-grade relative                      | 13 (5.6)<br>[0–15.6]           | 23 (5.3)<br>[0–11.3]           | 11 (3.1)<br>[0–9.0]            | 0.263 <sup>2</sup>               |
| - Third-grade relative                       | 10 (4.3)<br>[0–14.3]           | 7 (1.6) [0–7.6]                | 6 (1.7) [0–7.6]                | 0.059 <sup>2</sup>               |
| Past or current psychiatric treatment        | 48 (21.4)<br>[16.0–26.8]       | 89 (21.7)<br>[17.7–25.7]       | 29 (8.7)<br>[5.7–11.8]         | <0.001 <sup>2</sup><br>(b, c)    |
| DemTect                                      | 14.54 (±2.55)<br>[14.21–14.87] | 15.32 (±2.27)<br>[15.10–15.53] | 14.02 (±2.53)<br>[13.75–14.29] | <0.001 <sup>1</sup><br>(a, b, c) |
| - No cognitive impairment                    | 174 (76.0)<br>[70.0–82.0]      | 384 (89.7)<br>[86.7–92.7]      | 254 (74.9)<br>[69.8–80.1]      | <0.001 <sup>2</sup><br>(a, c)    |
| - Mild cognitive impairment                  | 52 (22.7)<br>[16.7–28.7]       | 43 (10.0)<br>[7.1–13.0]        | 79 (23.3)<br>[18.2–28.4]       | <0.001 <sup>2</sup><br>(a, c)    |
| - Suspected dementia                         | 3 (1.3) [0–7.3]                | 1 (0.2) [0–3.2]                | 6 (1.8) [0–6.9]                | 0.092 <sup>2</sup>               |

Numbers present either absolute numbers plus percent or mean plus standard deviation, 95 % confidence interval in square brackets; frequencies are given for the participants with valid data records for the respective measure; significant group difference between 50–59 y and 60–69 y (a), 50–59 y and 70–87 y (b) and 60–69 y and 70–87 y (c); BDI-II, Beck Depression Inventory II (depression cut-off BDI-II ≥ 14, no depression 0–8, minimal depression 9–13, mild depression 14–19, moderate depression 20–28, severe depression >28); DemTect, test for the early detection of cognitive impairment (no cognitive impairment >12, mild cognitive impairment 9–12, suspected dementia <9).

<sup>1</sup> Univariate ANOVA (two-tailed).

<sup>2</sup>  $\chi^2$ -test (two-tailed).

Table 4 shows descriptive statistics of clinical variables and depression-associated measures stratified by educational level. Most participants had an intermediate education level (N = 558, 54.9 %), only a few participants had a low level (N = 61, 6 %). Higher educated participants had significantly lower BDI-II and higher DemTect-scores. No significant differences were depicted regarding history or positive family of psychiatric treatment.




Fig. 1. Distribution of depression severity by age group and sex.

**Table 3**  
Descriptive statistics of clinical variables across females and males.

| Variables                                    | Females<br>N = 456<br>(44.8) | Males<br>N = 561<br>(55.2) | p-Value             |
|----------------------------------------------|------------------------------|----------------------------|---------------------|
| Clinical variables                           |                              |                            |                     |
| BDI-II                                       | 6.40 (±6.23)                 | 4.63 (±4.96)               | <0.001 <sup>1</sup> |
| Depression                                   | 41 (9.3)                     | 29 (5.4)                   | 0.019 <sup>2</sup>  |
| - No depression                              | 324 (73.3)                   | 446 (83.1)                 | <0.001 <sup>2</sup> |
| - Minimal depression                         | 77 (17.4)                    | 62 (11.5)                  | 0.009 <sup>2</sup>  |
| - Mild depression                            | 24 (5.4)                     | 20 (3.7)                   | 0.200 <sup>2</sup>  |
| - Moderate depression                        | 11 (2.5)                     | 7 (1.3)                    | 0.170 <sup>2</sup>  |
| - Severe depression                          | 6 (1.4)                      | 2 (0.4)                    | 0.088 <sup>2</sup>  |
| Positive family history for psych. disorders | 100 (22.2)                   | 82 (14.6)                  | 0.003 <sup>2</sup>  |
| - First-grade relative                       | 55 (12.1)                    | 52 (9.3)                   | 0.149 <sup>2</sup>  |
| - Second-grade relative                      | 30 (6.6)                     | 17 (3.0)                   | 0.007 <sup>2</sup>  |
| - Third-grade relative                       | 12 (2.6)                     | 11 (2.0)                   | 0.474 <sup>2</sup>  |
| Past or current psychiatric treatment        | 87 (19.8)                    | 79 (15.0)                  | 0.046 <sup>2</sup>  |
| DemTect                                      | 15.30<br>(±2.38)             | 14.21<br>(±2.47)           | <0.001 <sup>1</sup> |
| - No cognitive impairment                    | 395 (89.0)                   | 417 (75.5)                 | <0.001 <sup>2</sup> |
| - Mild cognitive impairment                  | 48 (10.8)                    | 126 (22.8)                 | <0.001 <sup>2</sup> |
| - Suspected dementia                         | 1 (0.2)                      | 9 (1.6)                    | 0.027 <sup>2</sup>  |

Numbers present either absolute numbers plus percent or mean plus standard deviation; frequencies are given for the participants with valid data records for the respective measure; BDI-II, Beck Depression Inventory II (depression cut-off BDI-II  $\geq 14$ , no depression 0–8, minimal depression 9–13, mild depression 14–19, moderate depression 20–28, severe depression  $>28$ ); DemTect, test for the early detection of cognitive impairment (no cognitive impairment  $>12$ , mild cognitive impairment 9–12, suspected dementia  $<9$ ).

<sup>1</sup> t-Test (two-tailed).

<sup>2</sup>  $\chi^2$ -test (two-tailed).

3.4. Differences between physical condition, medication and cognitive factors regarding depressive symptom severity

Lifestyle patterns reveal that regular physical activity declines with increasing depressive symptoms, and smoking tend to be higher among participants with manifest depressive symptoms. However, The BDI-II score was not significantly different between physically active and inactive participants or between smoking and non-smoking participants (Table 5). Participants with a life-time prevalence of illegal drug use reported significantly more depressive symptoms (Table 5). Regression analysis reveals that severity of depressive symptoms was not associated

with lifestyle factors such as physical activity in hours per week ( $r = -0.008$ ,  $p = 0.805$ ), number of cigarettes per day ( $r = 0.026$ ,  $p = 0.425$ ), and alcohol consumption ( $r = -0.008$ ,  $p = 0.794$ ).

Quality-of-life measures, such as the Nuremberg Life Quality Questionnaire (NLQ), demonstrate a notable decline in scores with increased depressive symptoms, indicating reduced perceived quality of life.

Inferential statistics showed that participants with history of psychiatric treatment reported significantly more depressive symptoms (Table 5) and that those with a positive family history of psychiatric disorders had significantly higher BDI-II scores (Table 2, S2).

Obesity, joint disease and polyneuropathy were all associated with higher BDI-II scores (Table S2). Participants taking antidepressants, vitamin D, antihypertensives, PPIs, and anticonvulsants had higher BDI-II scores than those not taking these drugs (Table 5).

Participants with suspected mild cognitive impairment had more depressive symptoms than those with either no cognitive impairment or suspected dementia (measured with the DemTect, a screening tool for cognitive decline (Kalbe et al., 2004), Table 5, S2). Furthermore, higher BDI-II scores were associated with significantly lower DemTect scores ( $\beta = 0.148$ ,  $p < 0.001$ ).

3.5. Prevalence of cognitive, affective and somatic depressive symptoms in the various age groups

Participants reported more about somatic symptoms ( $M = 3.59$ ;  $SD \pm 3.22$ ) than cognitive ( $M = 1.05$ ;  $SD \pm 1.87$ ) or affective symptoms ( $M = 0.79$ ;  $SD \pm 1.35$ ) in the BDI II (Fig. S1). Symptom severity of the somatic domain tend to increase across the age groups but did not differ significantly ( $F(2;954) = 0.449$ ,  $p = 0.638$ , Fig. S2). The age groups 50 to 59 years and 60 to 69 years exhibited significantly higher cognitive symptoms than the age group 70 years and older ( $F(2;955) = 6.265$ ,  $p = 0.002$ ). Furthermore, in the youngest age group, affective symptom severity was significantly higher than for the oldest age group ( $F(2;955) = 3.709$ ,  $p = 0.025$ ; Fig. S2).

4. Discussion

This study aimed to evaluate the prevalence of depressive symptoms and the association between depressive symptoms and clinical variables such as cognition, comorbidities and medication in older adults aged 50 and above. About a fifth (21.3 %) of participants had depressive symptoms (14.2 %, minimal; 4.5 %, mild; 1.8 %, moderate; and 0.8 %, severe). With increasing age, the prevalence of severe depressive

**Table 4**  
Descriptive statistics of clinical variables across educative levels.

| Variables                                    | Low education<br>N = 61<br>(6.0) | Intermediate education<br>N = 558 (54.9) | High education<br>N = 397<br>(39.1) | p-Value                       |
|----------------------------------------------|----------------------------------|------------------------------------------|-------------------------------------|-------------------------------|
| <b>Clinical variables</b>                    |                                  |                                          |                                     |                               |
| BDI-II                                       | 6.92<br>(±5.55)                  | 6.14 (±5.94)                             | 4.24<br>(±4.98)                     | <0.001 <sup>1</sup><br>(b, c) |
| Depression                                   | 6 (10.2)                         | 47 (8.8)                                 | 17 (4.4)                            | 0.023 <sup>2</sup> (c)        |
| - No depression                              | 43 (72.9)                        | 398 (74.8)                               | 328 (84.8)                          | 0.001 <sup>2</sup> (b, c)     |
| - Minimal depression                         | 10 (16.9)                        | 87 (16.4)                                | 42 (10.9)                           | 0.051 <sup>2</sup>            |
| - Mild depression                            | 5 (8.5)                          | 28 (5.3)                                 | 11 (2.8)                            | 0.068 <sup>2</sup>            |
| - Moderate depression                        | 0 (0.0)                          | 13 (2.4)                                 | 5 (1.3)                             | 0.244 <sup>2</sup>            |
| - Severe depression                          | 1 (1.7)                          | 6 (1.1)                                  | 1 (0.3)                             | 0.262 <sup>2</sup>            |
| Positive family history for psych. disorders | 7 (11.7)                         | 92 (16.8)                                | 83 (21.2)                           | 0.093 <sup>2</sup>            |
| - First-grade relative                       | 5 (8.2)                          | 52 (9.3)                                 | 50 (12.6)                           | 0.221 <sup>2</sup>            |
| - Second-grade relative                      | 2 (3.3)                          | 21 (3.8)                                 | 24 (6.0)                            | 0.223 <sup>2</sup>            |
| - Third-grade relative                       | 0 (0.0)                          | 16 (2.9)                                 | 7 (1.8)                             | 0.249 <sup>2</sup>            |
| Past or current psychiatric treatment        | 11 (18.6)                        | 90 (17.1)                                | 65 (17.0)                           | 0.951 <sup>2</sup>            |
| DemTect                                      | 14.07<br>(±2.84)                 | 14.44 (±2.53)                            | 15.16<br>(±2.30)                    | <0.001 <sup>1</sup><br>(b, c) |
| - No cognitive impairment                    | 37 (62.7)                        | 439 (80.8)                               | 336 (85.5)                          | <0.001 <sup>2</sup><br>(a, b) |
| - Mild cognitive impairment                  | 21 (35.6)                        | 96 (17.7)                                | 56 (14.2)                           | <0.001 <sup>2</sup><br>(a, b) |
| - Suspected dementia                         | 1 (1.7)                          | 8 (1.5)                                  | 1 (0.3)                             | 0.157 <sup>2</sup>            |

Numbers present either absolute numbers plus percent or mean plus standard deviation; frequencies are given for the participants with valid data records for the respective measure; significant group difference between low and intermediate (a), low and high (b) and intermediate and high education (c); BDI-II, Beck Depression Inventory II (depression cut-off BDI-II ≥ 14, no depression 0–8, minimal depression 9–13, mild depression 14–19, moderate depression 20–28, severe depression >28); DemTect, test for the early detection of cognitive impairment (no cognitive impairment >12, mild cognitive impairment 9–12, suspected dementia <9).

<sup>1</sup> Univariate ANOVA (two-tailed).

<sup>2</sup>  $\chi^2$ -test (two-tailed).

symptoms decreased and that of minimal depressive symptoms increased.

#### 4.1. Prevalence of depressive symptoms

We found a relatively high prevalence of depressive symptoms, which aligns with other studies: A meta-analysis showed a global prevalence of depressive symptoms of 19.47 % in people 50 years and older (Volkert et al., 2013), and a study found a global prevalence of depression of 28.4 % in older adults (Hu et al., 2022). However, prevalence varies with geographic region, screening tool, sample size, and study quality (Hu et al., 2022). Another study found that 6.1 % of cognitively healthy individuals aged 60 years and older had moderate to severe depressive symptoms as measured with the BDI-II (Krell-Roesch et al., 2018); this prevalence may be a little lower than that in our sample (7.2 %) because Krell-Roesch et al. excluded cognitively impaired individuals. Patients with comorbidities have a higher prevalence of depressive symptoms; for example, 20.3 % of patients with implantable cardioverter defibrillators and 35 % of those with heart failure showed mild to severe depressive symptoms measured with the

**Table 5**  
Results of ANOVA between several demographic, lifestyle and clinical factors regarding BDI-II.

| Between-subject factor                  | F            | df (between groups) | df (within groups) | p                | $\eta^2$     |
|-----------------------------------------|--------------|---------------------|--------------------|------------------|--------------|
| <b>Demographic variables</b>            |              |                     |                    |                  |              |
| <b>Sex</b>                              | <b>11.27</b> | <b>1</b>            | <b>974</b>         | <b>&lt;0.001</b> | <b>0.011</b> |
| Age group (years)                       | 0.76         | 2                   | 973                | 0.467            | 0.002        |
| Native language German                  | 1.99         | 1                   | 973                | 0.159            | 0.002        |
| <b>ISCED97</b>                          | <b>10.06</b> | <b>2</b>            | <b>973</b>         | <b>&lt;0.001</b> | <b>0.020</b> |
| <b>Living with partner</b>              | <b>5.54</b>  | <b>1</b>            | <b>964</b>         | <b>0.019</b>     | <b>0.006</b> |
| <b>Lifestyle variables</b>              |              |                     |                    |                  |              |
| Regular physical activity per week      | 0.69         | 1                   | 958                | 0.405            | 0.001        |
| Smoking                                 | 0.14         | 1                   | 958                | 0.709            | <0.001       |
| <b>Illegal drug consumption</b>         | <b>37.97</b> | <b>1</b>            | <b>958</b>         | <b>&lt;0.001</b> | <b>0.038</b> |
| <b>Clinical variables</b>               |              |                     |                    |                  |              |
| <b>Positive family history</b>          | <b>20.18</b> | <b>1</b>            | <b>958</b>         | <b>&lt;0.001</b> | <b>0.021</b> |
| <b>Antidepressant intake</b>            | <b>72.24</b> | <b>1</b>            | <b>972</b>         | <b>&lt;0.001</b> | <b>0.069</b> |
| <b>Past or current psych. treatment</b> | <b>86.24</b> | <b>1</b>            | <b>925</b>         | <b>&lt;0.001</b> | <b>0.085</b> |
| <b>DemTect classes</b>                  | <b>5.98</b>  | <b>2</b>            | <b>953</b>         | <b>0.003</b>     | <b>0.012</b> |
| <b>BMI classes</b>                      | <b>3.17</b>  | <b>2</b>            | <b>949</b>         | <b>0.043</b>     | <b>0.007</b> |
| <b>Somatic variables</b>                |              |                     |                    |                  |              |
| Age related hearing loss                | 0.76         | 1                   | 956                | 0.385            | 0.001        |
| Other hearing loss                      | 1.93         | 1                   | 955                | 0.165            | 0.002        |
| Hearing aid                             | 0.44         | 1                   | 954                | 0.509            | <0.001       |
| Cataract                                | 0.31         | 1                   | 939                | 0.576            | <0.001       |
| Glaucoma                                | 0.04         | 1                   | 917                | 0.851            | <0.001       |
| <b>Joint disease</b>                    | <b>9.27</b>  | <b>1</b>            | <b>958</b>         | <b>0.002</b>     | <b>0.010</b> |
| Artificial joint                        | 1.92         | 1                   | 957                | 0.166            | 0.002        |
| Disc prolapse                           | 1.61         | 1                   | 957                | 0.205            | 0.002        |
| <b>Polyneuropathy</b>                   | <b>22.05</b> | <b>1</b>            | <b>956</b>         | <b>&lt;0.001</b> | <b>0.023</b> |
| <b>Past or current neuro. treatment</b> | <b>21.55</b> | <b>1</b>            | <b>958</b>         | <b>&lt;0.001</b> | <b>0.022</b> |
| <b>Medication intake</b>                |              |                     |                    |                  |              |
| <b>General medication intake</b>        | <b>5.37</b>  | <b>1</b>            | <b>973</b>         | <b>0.021</b>     | <b>0.005</b> |
| <b>Antihypertensives</b>                | <b>4.34</b>  | <b>1</b>            | <b>973</b>         | <b>0.038</b>     | <b>0.004</b> |
| Lipid reducers                          | 0.19         | 1                   | 973                | 0.665            | 0.000        |
| <b>Proton pump inhibitors</b>           | <b>22.15</b> | <b>1</b>            | <b>973</b>         | <b>&lt;0.001</b> | <b>0.022</b> |
| Anticoagulants                          | 2.50         | 1                   | 973                | 0.114            | 0.003        |
| Antidiabetics                           | 0.16         | 1                   | 973                | 0.693            | 0.000        |
| Levothyroxine                           | 2.22         | 1                   | 973                | 0.136            | 0.002        |
| Analgesic agents                        | 2.38         | 1                   | 973                | 0.123            | 0.002        |
| Inhalers for lung diseases              | 0.19         | 1                   | 973                | 0.891            | 0.000        |
| Parkinson's drugs                       | 1.65         | 1                   | 973                | 0.200            | 0.002        |
| <b>Anticonvulsants</b>                  | <b>7.03</b>  | <b>1</b>            | <b>973</b>         | <b>0.008</b>     | <b>0.007</b> |
| <b>Vitamin D</b>                        | <b>11.56</b> | <b>1</b>            | <b>973</b>         | <b>&lt;0.001</b> | <b>0.012</b> |
| <b>Antidepressants</b>                  | <b>72.24</b> | <b>1</b>            | <b>972</b>         | <b>&lt;0.001</b> | <b>0.069</b> |

ANOVA = analysis of variance; BDI-II = Beck Depression Inventory II; ISCED97 = International Standard Classification of Education 97; BMI = body mass index (body weight in kg/body size in m<sup>2</sup>); DemTect = Test for the early detection of cognitive impairment; df = degrees of freedom; corrected for age, sex and ISCED97.

Significant variables in bold.

BDI-II (Ensslin et al., 2022; Dekker et al., 2014). The National Health and Nutrition Examination Survey (NHANES) reported that 20.1 % of adults aged 18 and older had significant depressive symptoms (score on the German Health Questionnaire for Patients [PHQ-9; Löwe et al., 2002], ≥ 5), most of which were mild (PHQ-9 score, 5–9) (Shim et al.,

2011). Unlike our study, NHANES found no significant age-related decrease in severe depressive symptoms. This difference may be due to the broader age groups in NHANES: All individuals aged 55 and older were combined into one group, which may have masked the age-related variations observed in our more granular age groupings.

The European Health Interview Survey Third Wave reported a prevalence of 8.22 % for relevant depressive symptoms in the general population aged 15 to over 75 years in Germany, with higher rates in women and adults aged 75 and older (Arias-de la Torre et al., 2023). However, the survey primarily collected data on moderate to severe depressive symptoms. Similar to our study, Busch et al. (2013) showed that severe depressive symptoms (measured with the PHQ-9) decreased with increasing age.

The clinical pictures and possible disease stages of depression are heterogeneous and include stages with undiagnosed depression, sub-threshold depression, cognitive decline, and the MDD prodromal state. Therefore, if studies focus only on moderate to severe symptoms (e.g., Busch et al., 2013; Arias-de la Torre et al., 2023), they may overlook a significant portion of the population at risk (Kessler et al., 2005). Evaluating mild depressive symptoms, as we did in our study, is crucial for several reasons: Such symptoms can be early indicators of more severe mental health issues, and studies have shown that individuals with mild depressive symptoms are at higher risk of developing MDD if their symptoms are not addressed early on (Cuijpers and Smit, 2004; Meeks et al., 2011). Early detection and intervention can prevent progression to more severe depression, and early intervention for mild symptoms can be less intensive and more cost effective than treating severe depression. Furthermore, mild depressive symptoms can also significantly impact an individual's quality of life, social relationships, and well-being (Judd et al., 1997) and are often associated with and can exacerbate chronic physical conditions, such as cardiovascular diseases and diabetes (Katon, 2011). Older adults have a high probability of remaining depressed for over a year (Thielke et al., 2010; Meeks et al., 2011). In summary, these findings support the increased focus on prevention (Cuijpers and Smit, 2008; Reynolds, 2008).

#### 4.2. Sociodemographic factors and depressive symptoms

Women and participants with a low level of education had significantly more depressive symptoms, which is in accordance with the findings of other studies (Djernes, 2006; Busch et al., 2013; Streit et al., 2023; Lozupone et al., 2022; Mardiana et al., 2022; Meeks et al., 2011). Cognitive performance was higher in participants with higher educational level. Especially in old age, a low educational level seems to be a risk factor for depression (Köhler et al., 2018) and also dementia (Livingston et al., 2020). Participants living with a partner described fewer depressive symptoms than single, divorced, or widowed participants. Another risk factor for MDD is the loss of spouse (Köhler et al., 2018; Schoevers et al., 2006).

#### 4.3. Psychiatric history and depressive symptoms

A history of psychiatric treatment and a positive family history of psychiatric disorders were associated with greater severity of depressive symptoms, which is in line with other studies (Streit et al., 2023; Biella et al., 2019). There were no differences between the educational level and history of psychiatric treatment or a positive family history of psychiatric disorders. However, since BDI-scores were higher in lower educated participants, a higher utilization of psychiatric treatment was expected. In our study, participants with a life-time prevalence of illegal drug use also had significantly more depressive symptoms. In our sample, 2.9 % of participants reported illegal drug use, and the 2001–2002 National Epidemiologic Survey of Alcohol and Related Conditions found a lifetime prevalence of non-medical drug use of <4 % in adults aged 65 years and older (Moore et al., 2009). Information on psychiatric comorbidity with substance use disorders in old age is scarce, but in

middle-aged and older individuals, alcohol and substance use disorders are associated with depression (Wu and Blazer, 2014). We found an association only between illegal drug use and greater depressive symptom severity.

#### 4.4. Cognition and depressive symptoms

Participants with cognitive impairment measured with the DemTect (Kalbe et al., 2004) had a greater severity of depressive symptoms. Furthermore, those with suspected mild impairment had more depressive symptoms than those with no impairment, which is in accordance with findings that depressive symptoms occur especially in the early phase of cognitive decline (Djernes, 2006). In late-life depression, impairments occur in verbal learning, memory, and motor speed (Thomas et al., 2009; Invernizzi et al., 2021). As pathomechanisms, changes in grey matter volume in the prefrontal, anterior cingulate cortex, striatum, and hippocampus and white matter hyperintensities are discussed (Invernizzi et al., 2021; Kim and Han, 2021).

Others showed that cortical amyloid deposition in cognitively healthy older adults was associated with higher odds of depression measured with the BDI (Krell-Roesch et al., 2018). Late-life depression is a risk factor for dementia and occurs in 50 % of patients with Alzheimer's disease (Livingston et al., 2020; Chi et al., 2014; Kuo et al., 2020). A depressive episode, especially in old age, increases the risk for dementia, and a meta-regression revealed that the risk decreases with the length of follow-up (Prince et al., 2014; Singh-Manoux et al., 2017; Almeida et al., 2017; Livingston et al., 2020). Therefore, Livingston et al. (2020) summarized that in old age, a reduction in cognitive reserve due to a depressive episode may increase the risk of developing dementia. Furthermore, brain neuroplasticity is assumed to be negatively influenced by oxidative stress, inflammation, and vascular changes during a depressive episode (Alexopoulos, 2019). Another bidirectional link is that depression and cognitive impairment are associated with reduced social activities and networks (Kelly et al., 2017; Taylor et al., 2018). To conclude, cognitive impairment may be a prodrome of not only Alzheimer's disease, but also late-life depression and depressive symptoms.

#### 4.5. Medication and depressive symptoms

Depressive symptoms were significantly associated with intake of medications, including antidepressants, vitamin D, antihypertensives, PPIs, and anticonvulsants. Quantity of somatic drug intake was associated with greater symptom severity, which is consistent with Qato et al. (2018) and Laudisio et al. (2018). Common side effects for antihypertensives, PPIs and analgesics are depression. Use of PPIs increased the probability of depression in participants aged 75 years and older even after correction for peptic diagnosis or antidepressant medication (Laudisio et al., 2018). Results of the Berlin Aging Study showed that 35.3 % of participants aged over 70 were being treated for at least five conditions: The most common was hypertension, followed by peripheral vascular disease, cardiac failure, hypercholesterolemia, and angina pectoris or myocardial infarction (Hillen et al., 2000). These findings suggest the need for careful monitoring of depressive symptoms, drug-drug interactions and monitoring for adverse reactions due to the lower tolerability in older adults with polypharmacy (Holvast et al., 2017).

#### 4.6. Chronic physical conditions and depressive symptoms

Depression was significantly associated with obesity, joint disease, and polyneuropathy. The risk for a depressive episode is twice as high in people with multimorbidity than in those without it and three times higher in those with chronic physical conditions than in those without them (Read et al., 2017). Various pathomechanisms can cause joint diseases and polyneuropathy, and inflammatory or cardiovascular diseases are often responsible; for example, rheumatoid arthritis, diabetes mellitus, and chronic kidney diseases often coexist with depression.

Dziemidok et al. (2023) found that depressive symptoms were associated with diabetic distal symmetric polyneuropathy and that in patients with this disease, depression severity correlated significantly with body mass index, severity of neuropathy symptoms, and lower education level. Furthermore, a large cohort study showed a higher risk for depression in painless diabetic polyneuropathy and particularly in painful diabetic polyneuropathy; neuropathic pain and its severity and cognitive processing (pain catastrophizing) were identified as dominant risk factors for depression (Kec et al., 2022). Chronic low-grade inflammation, insulin resistance, and impaired thrombogenesis are pathophysiological pathways in both depression and cardiovascular diseases (Chávez-Castillo et al., 2020, 2017) and the inflammatory pathways of depression and rheumatoid arthritis may also be linked (Nerurkar et al., 2019).

Obesity increases insulin resistance and often also leptin resistance, which causes a lack of satiety (Sáinz et al., 2015). In depression, leptin potentiates the hypothalamus-pituitary-adrenal axis and increases interleukin 6 and tumor necrosis factor alpha expression (Agrawal et al., 2011). Furthermore, expression of adiponectin, which is anti-inflammatory and upregulated by weight loss, was found to be down-regulated by glucocorticoid signaling, which could be interpreted as another link between depression and obesity (Taylor and Macqueen, 2010).

Polyneuropathy, joint disease, and obesity are all associated with physical decline. Depression itself accelerates the biological aging process and leads to cognitive and physical decline (Szymkowicz et al., 2023), which may explain why patients with both depression and frailty have higher mortality rates (Lugtenburg et al., 2021) and why comorbidities such as orthopedic disease or arthritis worsen outcome in patients with late-life depression (Uysal Cesur and Poyraz, 2023). Patients with somatic illnesses associated with physical decline should be monitored for depressive symptoms since they are associated with further reduction in quality in life and worsen outcome.

#### 4.7. Variations in cognitive, affective and somatic domains measured with the BDI-II

All age groups reported more about somatic symptoms than affective or cognitive. When comparing the age groups, there was no difference in the somatic domain. Common somatic symptoms in late-life Depression are sleep disturbance, fatigue, psychomotor retardation and cognitive complaints (Gallo et al., 1994; Christensen et al., 1999; Fiske et al., 2009). Other studies in younger and older populations showed that late-life somatic symptoms such as sleep and appetite disturbance, loss of energy, tiredness, and fatigue indicate depression, whereas weight loss and loss of interest in sex are related to aging (Norris et al., 2004; Koenig et al., 1993; Norris and Woehr, 1998).

When comparing the youngest to the oldest age group, affective symptoms seem to be less prominent in the oldest age group. Gallo et al. (1997) described depression in late-life as “depression without sadness”. Studies by Fisch (1987), Conwell et al. (1998), and Waern et al. (2003) indicate that older adults may exhibit “masked depression” and present with more somatic and cognitive complaints than those with “traditional” depressive symptoms. However, a big cross-sectional study in the general population aged 65 years in Europe showed that death wishes, depressed mood, loss of interest, and pessimism are main depressive symptoms in late-life, whereas insomnia, fatigue and appetite changes played a minor role (Belvederi Murri et al., 2020). Longitudinal analysis from this cohort depicted that changes in sad or depressed mood, reduced interest, and suicidal ideation were most associated with changes in the rest of the symptoms (Savelieva et al., 2021). However, in this studies depressive symptom dimensions were not stratified by age.

In our sample, cognitive-affective symptoms seem to decrease with growing age. Feelings of past failure or punishment appeared to decrease with increasing age, raising the question whether fear of failure or punishment decreases and the relevance of current emotional

conflicts increases as people age. Åström et al. (2019) also found a positive association between depressive symptoms and negative views of the past in older age but noted that with age, people become more concerned about the present than the future. In our study, suicidal thoughts were less common in older participants, which is consistent with Conwell et al. (2002), who found that older adults are less likely to communicate suicidal intent. Over half of adults aged 60 years and older are at risk of social isolation (Fakoya et al., 2020). Feelings of loneliness are linked to depression and suicidal behavior, especially in late life (Calati et al., 2019; Fakoya et al., 2020). A shift in symptom perception may explain why severe depressive symptoms decrease with increasing age and minimal ones increase.

Individuals in our study exhibited varying levels of depressive symptoms without meeting the criteria for clinical depression according to DSM-5 (American Psychiatric Association, 2013) or ICD-10 (World Health Organization, 1992). However, the presence of minimal to moderate depressive symptoms may indicate a possible prodromal state of depression and can also affect well-being. This concept is supported by research indicating that mild depressive symptoms can be clinically significant and affect quality of life and functioning (Judd et al., 1996; Cuijpers and Smit, 2004).

#### 4.8. Limitations

This study has several limitations, including the retrospective cross-sectional design. Further research needs to explore causality and changes over time longitudinally and to develop prediction models for transition to MDD. Another limitation is the self-rating of depressive symptoms; however, an evaluation of the BDI-II in inpatients aged 55 years and older with MDD or adjustment disorder with depressive mood showed high internal consistency (coefficient alpha, 0.89; Steer et al., 2000). In addition, adequate-to-high internal consistency was measured in older Americans (Gallagher et al., 1982) and community dwellers (Segal et al., 2008; Balsamo et al., 2018). The mean BDI score correlates significantly with the population prevalence of depression determined by a physician (Veerman et al., 2009). Prevalence rates in our sample were similar to other large population-based studies. Because of the high rates of minimal depressive symptoms, further research into early recognition and effective interventions for older adults at risk for worsening of depressive symptoms is urgently needed.

#### 5. Conclusion

Our study found that with increasing age, the prevalence of severe depressive symptoms decreases and that of minimal depressive symptoms increases. Symptoms such as feelings of failure, self-dislike, punishment, and changes in appetite appear to be less prominent in older adults. These findings suggest that symptomatology shifts as people age and emphasize the importance of recognizing and addressing depressive symptoms, which may be a prodrome for MDD.

Early detection of older individuals at high risk for MDD is crucial. Our data indicate that participants with low educational levels, a history of psychiatric or neurological treatment, lower cognitive functioning, obesity, joint disease, polyneuropathy, and use of PPIs and antihypertensives have higher severity of depressive symptoms. In older adults, chronic diseases significantly contribute to the risk of depressive symptoms.

To mitigate the above risks, it is essential to develop early detection and screening instruments tailored to older adults. Early detection instruments should address cognitive impairment, reduced quality of life, and lower functionality due to multimorbidity, and screening tools should address social isolation, loss of autonomy, and chronic pain. By focusing on these medical and psychosocial aspects, we may be able to better identify and support older adults at risk of developing more severe depressive conditions.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jad.2025.353363>.

[org/10.1016/j.jad.2024.12.099](https://doi.org/10.1016/j.jad.2024.12.099).

## CRediT authorship contribution statement

**Julia Christl:** Writing – original draft, Methodology, Formal analysis, Conceptualization. **Pascal Grumbach:** Visualization, Methodology, Formal analysis, Data curation. **Christiane Jockwitz:** Writing – review & editing, Validation, Methodology, Data curation, Conceptualization. **Natalia Wege:** Writing – review & editing, Validation. **Svenja Caspers:** Writing – review & editing, Supervision, Project administration, Conceptualization. **Eva Meisenzahl:** Writing – review & editing, Supervision, Conceptualization.

## Funding

This project has received funding from the European Union's Horizon Europe Programme under the Specific Grant Agreement No. 101147319 (EBRAINS 2.0 Project; SC).

## Declaration of competing interest

The authors have nothing to declare.

## Acknowledgements

The authors thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript.

## References

- Agrawal, S., Gollapudi, S., Su, H., Gupta, S., 2011. Leptin activates human B cells to secrete TNF- $\alpha$ , IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. *J. Clin. Immunol.* 31 (3), 472–478. <https://doi.org/10.1007/s10875-010-9507-1>.
- Alexopoulos, G.S., 2005. Depression in the elderly. *Lancet* (London, England) 365 (9475), 1961–1970. [https://doi.org/10.1016/S0140-6736\(05\)66665-2](https://doi.org/10.1016/S0140-6736(05)66665-2).
- Alexopoulos, G.S., 2019. Mechanisms and treatment of late-life depression. *Transl. Psychiatry* 9 (1), 188. <https://doi.org/10.1038/s41398-019-0514-6>.
- Almeida, O.P., Hankey, G.J., Yeap, B.B., Golledge, J., Flicker, L., 2017. Depression as a modifiable factor to decrease the risk of dementia. *Transl. Psychiatry* 7 (5), e1117. <https://doi.org/10.1038/tp.2017.90>.
- Almeida, S., Camacho, M., Barahona-Corrêa, J.B., Oliveira, J., Lemos, R., da Silva, D.R., da Silva, J.A., Baptista, T.M., Grácio, J., Oliveira-Maia, A.J., 2023. Criterion and construct validity of the Beck Depression Inventory (BDI-II) to measure depression in patients with cancer: the contribution of somatic items. *International Journal of Clinical and Health Psychology: IJCHP* 23 (2), 100350. <https://doi.org/10.1016/j.ijchp.2022.100350>.
- American Psychiatric Association, 2013. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed. American Psychiatric Publishing, Arlington, VA.
- Arias-de la Torre, J., Vilagut, G., Ronaldson, A., Bakolis, I., Dregan, A., Martín, V., Martínez-Alés, G., Molina, A.J., Serrano-Blanco, A., Valderas, J.M., Viana, M.C., Alonso, J., 2023. Prevalence and variability of depressive symptoms in Europe: update using representative data from the second and third waves of the European Health Interview Survey (EHIS-2 and EHIS-3). *Lancet Public Health* 8 (11), e889–e898. [https://doi.org/10.1016/S2468-2667\(23\)00220-7](https://doi.org/10.1016/S2468-2667(23)00220-7).
- Åström, E., Rönnlund, M., Adolfsson, R., Grazia Carelli, M., 2019. Depressive symptoms and time perspective in older adults: associations beyond personality and negative life events. *Aging Ment. Health* 23 (12), 1674–1683. <https://doi.org/10.1080/13607863.2018.1506743>.
- Aziz, R., Steffens, D.C., 2013. What are the causes of late-life depression? *Psychiatr. Clin. North Am.* 36 (4), 497–516. <https://doi.org/10.1016/j.psc.2013.08.001>.
- Balsamo, M., Cataldi, F., Carlucci, L., Padulo, C., Fairfield, B., 2018. Assessment of late-life depression via self-report measures: a review. *Clin. Interv. Aging* 13, 2021–2044. <https://doi.org/10.2147/CIA.S178943>.
- Belvederi Murri, M., Amore, M., Respingo, M., Alexopoulos, G.S., 2020. The symptom network structure of depressive symptoms in late-life: results from a European population study. *Mol. Psychiatry* 25 (7), 1447–1456. <https://doi.org/10.1038/s41380-018-0232-0>.
- Benasi, G., Fava, G.A., Guidi, J., 2021. Prodromal symptoms in depression: a systematic review. *Psychother. Psychosom.* 90 (6), 365–372. <https://doi.org/10.1159/000517953>.
- Biella, M.M., Borges, M.K., Strauss, J., Mauer, S., Martinelli, J.E., Aprahamian, I., 2019. Subthreshold depression needs a prime time in old age psychiatry? A narrative review of current evidence. *Neuropsychiatr. Dis. Treat.* 23 (15), 2763–2772. <https://doi.org/10.2147/NDT.S223640>.
- Blazer, D.G., 2003. Depression in late life: review and commentary. *J. Gerontol. A Biol. Sci. Med. Sci.* 58 (3), 249–265. <https://doi.org/10.1093/gerona/58.3.m249>.
- Blazer, D., Hughes, D.C., George, L.K., 1987. The epidemiology of depression in an elderly community population. *Gerontologist* 27 (3), 281–287. <https://doi.org/10.1093/geront/27.3.281>.
- Bridwell, D.A., Steele, V.R., Maurer, J.M., Kiehl, K.A., Calhoun, V.D., 2015. The relationship between somatic and cognitive-affective depression symptoms and error-related ERPs. *J. Affect. Disord.* 172, 89–95. <https://doi.org/10.1016/j.jad.2014.09.054>.
- Burgut, F.T., Benaour, M., Hencliff, C., 2006. Late-life depression: a neuropsychiatric approach. *Expert. Rev. Neurother.* 6 (1), 65–72. <https://doi.org/10.1586/14737175.6.1.65>.
- Busch, M.A., Maske, U.E., Ryl, L., Schlack, R., Hapke, U., 2013. Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1) [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. *Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz* 56 (5–6), 733–739. <https://doi.org/10.1007/s00103-013-1688-3>.
- Calati, R., Ferrari, C., Brittner, M., Oasi, O., Olié, E., Carvalho, A.F., Courtet, P., 2019. Suicidal thoughts and behaviors and social isolation: a narrative review of the literature. *J. Affect. Disord.* 245, 653–667. <https://doi.org/10.1016/j.jad.2018.11.022>.
- Caspers, S., Moebus, S., Lux, S., Pundt, N., Schütz, H., Mühleisen, T.W., Gras, V., Eickhoff, S.B., Romanzetti, S., Stöcker, T., Stirnberg, R., Kirlangic, M.E., Minnerop, M., Pieperhoff, P., Mödler, U., Das, S., Evans, A.C., Jöckel, K.H., Erbel, R., Cichon, S., et al., 2014. Studying variability in human brain aging in a population-based German cohort-rationale and design of 1000BRAINS. *Front. Aging Neurosci.* 6, 149. <https://doi.org/10.3389/fnagi.2014.00149>.
- Chávez-Castillo, M., Martínez, M.S., Calvo, M.J., Rojas, M., Núñez, V., Lameda, V.A., 2017. Chronic state of systemic stress: the link between depression and cardiovascular disease? *SM Journal of Clinical Medicine*. 3 (2), 1025.
- Chávez-Castillo, M., Nava, M., Ortega, A., Rojas, M., Núñez, V., Salazar, J., Bermúdez, V., Rojas-Quintero, J., 2020. Depression as an immunometabolic disorder: exploring shared pharmacotherapeutics with cardiovascular disease. *Curr. Neuropharmacol.* 18 (11), 1138–1153. <https://doi.org/10.2174/1570159X18666200413144401>.
- Chi, S., Yu, J.T., Tan, M.S., Tan, L., 2014. Depression in Alzheimer's disease: epidemiology, mechanisms, and management. *Journal of Alzheimer's Disease: JAD* 42 (3), 739–755. <https://doi.org/10.3233/JAD-140324>.
- Christensen, H., Jorm, A.F., Mackinnon, A.J., Korten, A.E., Jacomb, P.A., Henderson, A. S., Rodgers, B., 1999. Age differences in depression and anxiety symptoms: a structural equation modelling analysis of data from a general population sample. *Psychol. Med.* 29 (2), 325–339. <https://doi.org/10.1017/s0033291798008150>.
- Conwell, Y., Duberstein, P.R., Cox, C., Herrmann, J., Forbes, N., Caine, E.D., 1998. Age differences in behaviors leading to completed suicide. *The American Journal of Geriatric Psychiatry: official journal of the American Association for Geriatric Psychiatry* 6 (2), 122–126.
- Conwell, Y., Duberstein, P.R., Caine, E.D., 2002. Risk factors for suicide in later life. *Biol. Psychiatry* 52 (3), 193–204. [https://doi.org/10.1016/S0006-3223\(02\)01347-1](https://doi.org/10.1016/S0006-3223(02)01347-1).
- Cuijpers, P., Smit, F., 2004. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. *Acta Psychiatr. Scand.* 109 (5), 325–331. <https://doi.org/10.1111/j.1600-0447.2004.00301.x>.
- Cuijpers, P., Smit, F., 2008. Has time come for broad-scale dissemination for prevention of depressive disorders? *Acta Psychiatr. Scand.* 118 (6), 419–420. <https://doi.org/10.1111/j.1600-0447.2008.01294.x>.
- Dekker, R.L., Lennie, T.A., Doering, L.V., Chung, M.L., Wu, J.R., Moser, D.K., 2014. Coexisting anxiety and depressive symptoms in patients with heart failure. *Eur. J. Cardiovasc. Nurs.* 13 (2), 168–176. <https://doi.org/10.1177/1474515113519520>.
- Djernes, J.K., 2006. Prevalence and predictors of depression in populations of elderly: a review. *Acta Psychiatr. Scand.* 113 (5), 372–387. <https://doi.org/10.1111/j.1600-0447.2006.00770.x>.
- Dziemidok, P., Gorczyca-Siadak, D., Makara-Studzinska, M., 2023. Demographic and clinical factors associated with depression in 140 hospitalized diabetic patients with distal symmetric polyneuropathy evaluated using Beck Depression Inventory and 6-Item Neuropsychiatric Total Symptom Score Questionnaire. *Medical Science Monitor: international medical journal of experimental and clinical research* 29, e939043. <https://doi.org/10.12659/MSM.939043>.
- Ensslin, C., Berg, J., Hermes-Lauer, J., Keller, L.S., Niederseer, D., Pazhenkottil, A., von Känel, R., Schmied, C., 2022. Depressive symptoms in patients after primary and secondary prophylactic ICD implantation. *Clinical Research in Cardiology: official journal of the German Cardiac Society* 111 (11), 1210–1218. <https://doi.org/10.1007/s00392-021-01940-w>.
- Fahrenberg, J., Hampel, R., Selg, H., 2010. *FPI-R Freiburger Persönlichkeitsinventar*, 8th, Expanded edn. Hogrefe, Göttingen.
- Fakoya, O.A., McCorry, N.K., Donnelly, M., 2020. Loneliness and social isolation interventions for older adults: a scoping review of reviews. *BMC Public Health* 20 (1), 129. <https://doi.org/10.1186/s12889-020-8251-6>.
- Fisch, R.Z., 1987. Masked depression: its interrelations with somatization, hypochondriasis and conversion. *Int. J. Psychiatry Med.* 17 (4), 367–379. <https://doi.org/10.2190/cr7j-wu5n-hc5x-2jq5>.
- Fiske, A., Wetherell, J.L., Gatz, M., 2009. Depression in older adults. *Annu. Rev. Clin. Psychol.* 5, 363–389. <https://doi.org/10.1146/annurev.clinpsy.032408.153621>.
- Gallagher, D., Nies, G., Thompson, L.W., 1982. Reliability of the Beck Depression Inventory with older adults. *J. Consult. Clin. Psychol.* 50 (1), 152–153. <https://doi.org/10.1037/0022-006x.50.1.152>.
- Gallo, J.J., Anthony, J.C., Muthén, B.O., 1994. Age differences in the symptoms of depression: a latent trait analysis. *J. Gerontol.* 49 (6), P251–P264. <https://doi.org/10.1093/geronj/49.6.p251>.

- Gallo, J.J., Rabins, P.V., Lyketsos, C.G., Tien, A.Y., Anthony, J.C., 1997. Depression without sadness: functional outcomes of nondysphoric depression in later life. *J. Am. Geriatr. Soc.* 45 (5), 570–578. <https://doi.org/10.1111/j.1532-5415.1997.tb03089.x>.
- Gold, S.M., Köhler-Forsberg, O., Moss-Morris, R., Mehnert, A., Miranda, J.J., Bullinger, M., Steptoe, A., Whooley, M.A., Otte, C., 2020. Comorbid depression in medical diseases. *Nat. Rev. Dis. Primers* 6 (1), 69. <https://doi.org/10.1038/s41572-020-0200-2>.
- Hautzinger, M., Keller, F., Kühner, C., 2006. *BDI-II Beck Depressions-Inventar*, 2nd edn. Harcourt Test Services, Frankfurt.
- Hillen, T., Nieczaj, R., Münzberg, H., Schaub, R., Borchelt, M., Steinhagen-Thiessen, E., 2000. Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study. *J. Intern. Med.* 247 (6), 679–688. <https://doi.org/10.1046/j.1365-2796.2000.00681.x>.
- Holvast, F., van Hattem, B.A., Sinnige, J., Schellevis, F., Taxis, K., Burger, H., Verhaak, P. F.M., 2017. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study. *Fam. Pract.* 34 (5), 539–545. <https://doi.org/10.1093/fampra/cmz018>.
- Hu, T., Zhao, X., Wu, M., Li, Z., Luo, L., Yang, C., Yang, F., 2022. Prevalence of depression in older adults: a systematic review and meta-analysis. *Psychiatry Res.* 311, 114511. <https://doi.org/10.1016/j.psychres.2022.114511>.
- Invernizzi, S., Simoes Loureiro, I., Kandana Arachchige, K.G., Lefebvre, L., 2021. Late-life depression, cognitive impairment, and relationship with Alzheimer's disease. *Dement. Geriatr. Cogn. Disord.* 50 (5), 414–424. <https://doi.org/10.1159/000519453>.
- James, S.L., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdella, J., Abdelalim, A., et al., 2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392 (10159), 1789–1858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7) (Nov 10).
- Judd, L.L., Akiskal, H.S., Paulus, M.P., 1997. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. *J. Affect. Disord.* 45 (1–2), 5–18. [https://doi.org/10.1016/S0165-0327\(97\)00055-4](https://doi.org/10.1016/S0165-0327(97)00055-4).
- Kalbe, E., Kessler, J., Calabrese, P., Smith, R., Passmore, A.P., Brand, M., et al., 2004. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. *Int. J. Geriatr. Psychiatry* 19, 136–143. <https://doi.org/10.1002/gps.1042>.
- Kamtsiuris, P., Lange, M., Hoffmann, R., Schaffrath Rosario, A., Dahm, S., Kuhnert, R., Kurth, B.M., 2013. Die erste Welle der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1): Stichprobendesign, Response, Gewichtung und Repräsentativität [The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness]. *Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz* 56 (5–6), 620–630. <https://doi.org/10.1007/s00103-012-1650-9>.
- Katon, W.J., 2011. Epidemiology and treatment of depression in patients with chronic medical illness. *Dialogues Clin. Neurosci.* 13 (1), 7–23. <https://doi.org/10.31887/DCNS.2011.13.1/wkaton>.
- Kec, D., Rajdova, A., Raputova, J., Adamova, B., Srotova, I., Nekvapilova, E.K., Michalcakova, R.N., Horakova, M., Belobradkova, J., Olsovsky, J., Weber, P., Hajas, G., Kaiserova, M., Mazanec, R., Potockova, V., Ehler, E., Forgac, M., Birklein, F., Üçeyler, N., Sommer, C., et al., 2022. Risk factors for depression and anxiety in painful and painless diabetic polyneuropathy: a multicentre observational cross-sectional study. *European Journal of Pain* (London, England) 26 (2), 370–389. <https://doi.org/10.1002/ejp.1865>.
- Kelly, M.E., Duff, H., Kelly, S., McHugh Power, J.E., Brennan, S., Lawlor, B.A., Loughrey, D.G., 2017. The impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults: a systematic review. *Syst. Rev.* 6 (1), 259. <https://doi.org/10.1186/s13643-017-0632-2>.
- Kertesz, A., Davidson, W., Fox, H., 1997. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. *Can. J. Neurol. Sci.* 24, 29–36.
- Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch. Gen. Psychiatry* 62 (6), 593–602. <https://doi.org/10.1001/archpsyc.62.6.593>.
- Kim, Y.K., Han, K.M., 2021. Neural substrates for late-life depression: a selective review of structural neuroimaging studies. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 104, 110010. <https://doi.org/10.1016/j.pnpbp.2020.110010>.
- Koenig, H.G., Cohen, H.J., Blazer, D.G., Krishnan, K.R.R., Sibert, T.E., 1993. Profile of depressive symptoms in younger and older medical inpatients with major depression. *J. Am. Geriatr. Soc.* 41, 1169–1176.
- Köhler, C.A., Evangelou, E., Stubbs, B., Solmi, M., Veronese, N., Belbasis, L., Bortolato, B., Melo, M.C.A., Coelho, C.A., Fernandes, B.S., Olfson, M., Ioannidis, J.P. A., Carvalho, A.F., 2018. Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. *J. Psychiatr. Res.* 103, 189–207. <https://doi.org/10.1016/j.jpsychires.2018.05.020>.
- Kowall, B., Lehnich, A.T., Schramm, S., Schmidt, B., Erbel, R., Jöckel, K.H., Stang, A., 2021. Family aggregation of sleep characteristics: results of the Heinz Nixdorf Recall and the Multi-Generation Study. *PLoS One* 16 (6), e0252828. <https://doi.org/10.1371/journal.pone.0252828>.
- Krell-Roesch, J., Lowe, V.J., Neureiter, J., Pink, A., Roberts, R.O., Mielke, M.M., Vemuri, P., Stokin, G.B., Christianson, T.J., Jack, C.R., Knopman, D.S., Boeve, B.F., Kremers, W.K., Petersen, R.C., Geda, Y.E., 2018. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. *Int. Psychogeriatr.* 30 (2), 245–251. <https://doi.org/10.1017/S1041610217002368>.
- Kuo, C.Y., Stachiv, I., Nikolai, T., 2020. Association of late life depression, (non-) modifiable risk and protective factors with dementia and Alzheimer's disease: literature review on current evidences, preventive interventions and possible future trends in prevention and treatment of dementia. *Int. J. Environ. Res. Public Health* 17 (20), 7475. <https://doi.org/10.3390/ijerph17207475>.
- Laudisio, A., Antonelli Incalzi, R., Gemma, A., Giovannini, S., Lo Monaco, M.R., Vetrano, D.L., Padua, L., Bernabei, R., Zuccalà, G., 2018. Use of proton-pump inhibitors is associated with depression: a population-based study. *Int. Psychogeriatr.* 30 (1), 153–159. <https://doi.org/10.1017/S1041610217001715>.
- Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S.G., Dias, A., Fox, N., Gitlin, L.N., Howard, R., Kales, H.C., Kivimäki, M., Larson, E.B., Ogunniyi, A., Orgeta, V., et al., 2020. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* (London, England) 396 (10248), 413–446. [https://doi.org/10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6).
- Löwe, B., Spitzer, R.L., Zipfel, S., Herzog, W., 2002. *Gesundheitsfragebogen für Patienten (PHQ-D). Komplettversion und Kurzform. Testmappe mit Manual, Fragebögen, Schablonen*, 2. Aufl. Pfizer, Karlsruhe.
- Lozupone, M., D'Urso, F., Copetti, M., Sardone, R., Arcuti, S., Castellana, F., Galizia, I., Lofano, L., Veneziani, F., Piccininni, C., Barulli, M.R., Grasso, A., Battista, P., Tortelli, R., Capozzo, R., Griseta, C., Doricchi, F., Quaranta, N., Resta, E., Daniele, A., et al., 2022. The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. *Psychiatry Res.* 308, 114346. <https://doi.org/10.1016/j.psychres.2021.114346>.
- Lugtenburg, A., Zuidersma, M., Wardenaar, K.J., Aprahamian, I., Rhebergen, D., Schoevers, R.A., Oude Voshaar, R.C., 2021. Subtypes of late-life depression: a data-driven approach on cognitive domains and physical frailty. *J. Gerontol. A Biol. Sci. Med. Sci.* 76 (1), 141–150. <https://doi.org/10.1093/gerona/glaa110>.
- Luppa, M., Sikorski, C., Luck, T., Ehreke, L., Konnopka, A., Wiese, B., Weyerer, S., König, H.H., Riedel-Heller, S.G., 2012. Age- and gender-specific prevalence of depression in latest-life—systematic review and meta-analysis. *J. Affect. Disord.* 136 (3), 212–221. <https://doi.org/10.1016/j.jad.2010.11.033>.
- Mardiana, L., Astuti, P.A.S., Suariyani, N.L.P., Wirawan, D.N., 2022. Disability and lower social gradient increased risk of depression among pre-elderly in Indonesia: finding from a nationwide health and socio-economic survey. *Asia Pac. J. Public Health* 34 (5), 501–509. <https://doi.org/10.1177/10105395221090047>.
- Mathers, C.D., Loncar, D., 2006. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 3 (11), e442. <https://doi.org/10.1371/journal.pmed.0030442>.
- Meeks, T.W., Vahia, I.V., Lavretsky, H., Kulkarni, G., Jeste, D.V., 2011. A tune in “a minor” can “b major”: a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. *J. Affect. Disord.* 129 (1–3), 126–142. <https://doi.org/10.1016/j.jad.2010.09.015>.
- Meisenzahl, E., Wege, N., Stegmüller, V., Schulte-Körne, G., Greimel, E., Dannlowski, U., Hahn, T., Romer, G., Romanos, M., Deserno, L., Klingele, C., Theisen, C., Kieckhafer, C., Forstner, A., Ruhmann, S., Schultze-Lutter, F., 2024. Clinical high risk state of major depressive episodes: assessment of prodromal phase, its occurrence, duration and symptom patterns by the instrument the DEpression Early Prediction-Inventory (DEEP-IN). *J. Affect. Disord.* 351, 403–413. <https://doi.org/10.1016/j.jad.2023.12.084>.
- Moore, A.A., Karno, M.P., Grella, C.E., Lin, J.C., Warda, U., Liao, D.H., Hu, P., 2009. Alcohol, tobacco, and nonmedical drug use in older U.S. adults: data from the 2001/02 national epidemiologic survey of alcohol and related conditions. *J. Am. Geriatr. Soc.* 57 (12), 2275–2281. <https://doi.org/10.1111/j.1532-5415.2009.02554.x>.
- Nerurkar, L., Siebert, S., McInnes, I.B., Cavanagh, J., 2019. Rheumatoid arthritis and depression: an inflammatory perspective. *Lancet Psychiatry* 6 (2), 164–173. [https://doi.org/10.1016/S2215-0366\(18\)30255-4](https://doi.org/10.1016/S2215-0366(18)30255-4).
- Norris, M.P., Woehr, M.D., 1998. Differentiating somatic symptoms in the elderly: depression, aging, or illness? *Journal of Mental Health and Aging* 4, 347–359.
- Norris, M.P., Arnao, R.C., Bramson, R., Meagher, M.W., 2004. The efficacy of somatic symptoms in assessing depression in older primary care patients. *Clin. Gerontol.* 27 (1–2), 43–57. [https://doi.org/10.1300/J018v27n01\\_05](https://doi.org/10.1300/J018v27n01_05).
- Oswald, W.D., Fleischmann, U.M., 1997. *Nürnberger-Alters-Inventar (NAI). Hogrefe, Göttingen*.
- Penninx, B.W., Milanese, Y., Lamers, F., Vogelzangs, N., 2013. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Med.* 11, 129. <https://doi.org/10.1186/1741-7015-11-129>.
- Prince, M.J.A., Albanese, E., Guerchet, M., Prina, M., 2014. *The World Alzheimer Report 2014. Dementia and Risk Reduction. An Analysis of Protective and Modifiable Factors*. Alzheimer's Disease International, London.
- Qato, D.M., Ozenberger, K., Olfson, M., 2018. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. *JAMA* 319 (22), 2289–2298. <https://doi.org/10.1001/jama.2018.6741>.
- Read, J.R., Sharpe, L., Modini, M., Dear, B.F., 2017. Multimorbidity and depression: a systematic review and meta-analysis. *J. Affect. Disord.* 221, 36–46. <https://doi.org/10.1016/j.jad.2017.06.009>.
- Reynolds 3rd, C.F., 2008. Preventing depression in old age: it's time. *The American Journal of Geriatric Psychiatry: official journal of the American Association for Geriatric Psychiatry* 16 (6), 433–434. <https://doi.org/10.1097/JGP.0b013e31816c7b67>.

- Sáinz, N., Barrenetxe, J., Moreno-Aliaga, M.J., Martínez, J.A., 2015. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. *Metab. Clin. Exp.* 64 (1), 35–46. <https://doi.org/10.1016/j.metabol.2014.10.015>.
- Savelieva, K., Komulainen, K., Elovainio, M., Jokela, M., 2021. Longitudinal associations between specific symptoms of depression: network analysis in a prospective cohort study. *J. Affect. Disord.* 278, 99–106. <https://doi.org/10.1016/j.jad.2020.09.024>.
- Scheidt-Nave, C., Kamtsiuris, P., Gößwald, A., Hölling, H., Lange, M., Busch, M.A., Dahm, S., Dölle, R., Ellert, U., Fuchs, J., Hapke, U., Heidemann, C., Knopf, H., Laussmann, D., Mensink, G.B., Neuhauser, H., Richter, A., Sass, A.C., Rosario, A.S., Stolzenberg, H., et al., 2012. German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave. *BMC Public Health* 12, 730. <https://doi.org/10.1186/1471-2458-12-730>.
- Schmermund, A., Möhlenkamp, S., Stang, A., Grönemeyer, D., Seibel, R., Hirche, H., Mann, K., Siffert, W., Lauterbach, K., Siegrist, J., Jöckel, K.H., Erbel, R., 2002. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. *Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am. Heart J.* 144 (2), 212–218. <https://doi.org/10.1067/mhj.2002.123579> (Copy).
- Schoevers, R.A., Smit, F., Deeg, D.J., Cuijpers, P., Dekker, J., van Tilburg, W., Beekman, A.T., 2006. Prevention of late-life depression in primary care: do we know where to begin? *Am. J. Psychiatry* 163 (9), 1611–1621. <https://doi.org/10.1176/ajp.2006.163.9.1611>.
- Segal, D.L., Coolidge, F.L., Cahill, B.S., O'Riley, A.A., 2008. Psychometric properties of the Beck Depression Inventory II (BDI-II) among community-dwelling older adults. *Behav. Modif.* 32 (1), 3–20. <https://doi.org/10.1177/014545507303833>.
- Shim, R.S., Baltrus, P., Ye, J., Rust, G., 2011. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. *J. Am. Board Fam. Med.* 24 (1), 33–38. <https://doi.org/10.3122/jabfm.2011.01.100121>.
- Singh-Manoux, A., Dugravot, A., Fournier, A., Abell, J., Ebmeier, K., Kivimäki, M., Sabia, S., 2017. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. *JAMA Psychiatry* 74 (7), 712–718. <https://doi.org/10.1001/jamapsychiatry.2017.0660>.
- Steer, R.A., Rissmiller, D.J., Beck, A.T., 2000. Use of the Beck Depression Inventory-II with depressed geriatric inpatients. *Behav. Res. Ther.* 38 (3), 311–318. [https://doi.org/10.1016/s0005-7967\(99\)00068-6](https://doi.org/10.1016/s0005-7967(99)00068-6).
- Steffens, D.C., Fisher, G.G., Langa, K.M., Potter, G.G., Plassman, B.L., 2009. Prevalence of depression among older Americans: the Aging, Demographics and Memory Study. *International Psychogeriatrics* 21 (5), 879–888. <https://doi.org/10.1017/S1041610209990044>.
- Storch, E.A., Roberti, J.W., Roth, D.A., 2004. Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students. *Depress. Anxiety* 19 (3), 187–189. <https://doi.org/10.1002/da.20002>.
- Streit, F., Zillich, L., Frank, J., Kleineidam, L., Wagner, M., Baune, B.T., Klinger-König, J., Grabe, H.J., Pabst, A., Riedel-Heller, S.G., Schmiedek, F., Schmidt, B., Erhardt, A., Deckert, J., Investigators, N.A.K.O., Rietschel, M., Berger, K., 2023. Lifetime and current depression in the German National Cohort (NAKO). *The World Journal of Biological Psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry* 24 (10), 865–880. <https://doi.org/10.1080/15622975.2021.2014152>.
- Strine, T.W., Mokdad, A.H., Balluz, L.S., Gonzalez, O., Crider, R., Berry, J.T., Kroenke, K., 2008. Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. *Psychiatric Services (Washington, D.C.)* 59 (12), 1383–1390. <https://doi.org/10.1176/ps.2008.59.12.1383>.
- Szymkowicz, S.M., Gerlach, A.R., Homiack, D., Taylor, W.D., 2023. Biological factors influencing depression in later life: role of aging processes and treatment implications. *Transl. Psychiatry* 13 (1), 160. <https://doi.org/10.1038/s41398-023-02464-9>.
- Taylor, V.H., Macqueen, G.M., 2010. The role of adipokines in understanding the associations between obesity and depression. *J. Obes.* 2010, 748048. <https://doi.org/10.1155/2010/748048>.
- Taylor, W.D., Aizenstein, H.J., Alexopoulos, G.S., 2013. The vascular depression hypothesis: mechanisms linking vascular disease with depression. *Mol. Psychiatry* 18 (9), 963–974. <https://doi.org/10.1038/mp.2013.20>.
- Taylor, H.O., Taylor, R.J., Nguyen, A.W., Chatters, L., 2018. Social isolation, depression, and psychological distress among older adults. *J. Aging Health* 30 (2), 229–246. <https://doi.org/10.1177/0898264316673511>.
- Thielke, S.M., Diehr, P., Unutzer, J., 2010. Prevalence, incidence, and persistence of major depressive symptoms in the Cardiovascular Health Study. *Aging Ment. Health* 14 (2), 168–176. <https://doi.org/10.1080/13607860903046537>.
- Thomas, A.J., Gallagher, P., Robinson, L.J., Porter, R.J., Young, A.H., Ferrier, I.N., O'Brien, J.T., 2009. A comparison of neurocognitive impairment in younger and older adults with major depression. *Psychol. Med.* 39 (5), 725–733. <https://doi.org/10.1017/S0033291708004042>.
- UNESCO United Nations Educational, Scientific and Cultural Organization, 2003. *International Standard Classification of Education, ISCED 1997. Advances in Cross-national Comparison: A European Working Book for Demographic and Socio-economic Variables*, pp. 195–220.
- United Nations Department of Economic and Social Affairs, Population Division, 2022. *World Population Prospects 2022: summary of results*. UN DESA/POP/2022/TR/NO. wpp2022\_summary\_of\_results.pdf. [un.org](https://un.org). (Accessed 6 August 2024) (3).
- Uysal Cesur, N., Poyraz, B.Ç., 2023. Three-year prognosis of late-life depression in an outpatient geriatric psychiatry clinic: medical comorbidities worsen outcomes. *Psychiatry Q.* 94 (4), 675–689. <https://doi.org/10.1007/s11126-023-10053-8>.
- Veerman, J.L., Dowrick, C., Ayuso-Mateos, J.L., Dunn, G., Barendregt, J.J., 2009. Population prevalence of depression and mean Beck Depression Inventory score. *Br. J. Psychiatry J. Ment. Sci.* 195 (6), 516–519. <https://doi.org/10.1192/bjp.bp.109.066191>.
- Volkert, J., Schulz, H., Härter, M., Włodarczyk, O., Andreas, S., 2013. The prevalence of mental disorders in older people in Western countries - a meta-analysis. *Ageing Res. Rev.* 12 (1), 339–353. <https://doi.org/10.1016/j.arr.2012.09.004>.
- Waern, M., Rubenowitz, E., Runeson, B., Skoog, I., Wilhelmson, K., Allebeck, P., 2003. Burden of illness and suicide in elderly people: case-control study. *BMJ* 327 (7405), 1355.
- World Health Organization, 1992. *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. World Health Organization, Geneva.
- Wu, L.T., Blazer, D.G., 2014. Substance use disorders and psychiatric comorbidity in mid and later life: a review. *Int. J. Epidemiol.* 43 (2), 304–317. <https://doi.org/10.1093/ije/dyt173>.